ReviewInternational journal of molecular sciences2019
Chemerin Isoforms and Activity in Obesity.
Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
104 citing papers in PubMed, 3 syntheses or guidelines pooled it, 163 citations in OpenAlex.
- Salivary Lactate Dehydrogenase, Matrix Metalloproteinase-9, and Chemerin-The Most Promising Biomarkers for Oral Cancer? A Systematic Review with Meta-Analysis.International journal of molecular sciences · 2025Pooled it
- Raised levels of chemerin in women with preeclampsia: A meta-analysis.Biomolecules & biomedicine · 2024Pooled it
- New Mediators in the Crosstalk between Different Adipose Tissues.International journal of molecular sciences · 2024Pooled it
- Tissue-Specific Chemerin in Atherosclerosis.Biomolecules · 2026Review
- Reduced Serum Endostatin in Premenopausal Women with Lipedema Suggests Altered Vascular Homeostasis.Diseases (Basel, Switzerland) · 2026Article
- Decoding chemerin proteolytic processing and isoform signaling across disease contexts.iScience · 2026Review
- Transforming growth factor beta reduces proprotein convertase subtilisin/kexin type 9 in the supernatant of hepatic stellate cells.World journal of hepatology · 2026Article
- Adipokine networks in diabetic kidney disease: mechanistic insights and therapeutic implications.Lipids in health and disease · 2026Review
- Chemerin Normal Function and Roles in Metabolic and Nonmetabolic Disorders: An Up-To-Date Comprehensive Review.Biochemistry research international · 2026Review
- Chemerin/ChemerinR1 axis and inflammation-related diseases.Frontiers in molecular biosciences · 2026Review
- Chemerin as a Mediator of Hypertension and Cardiometabolic Diseases (A Comprehensive Review).Current hypertension reports · 2025Review
- Chemerin Exacerbates Pulmonary Inflammation in Type 2 Diabetes and Mycobacterium Tuberculosis Infection Comorbidity.Inflammation · 2025Article
- Chemerin and Asprosin as Promising Biomarkers of Metabolic Syndrome: A Scoping Review.Current obesity reports · 2025Article
- Chemerin and the Gut: From Inflammation to Cancer.Biomedicines · 2025Review
- Chemerin 15 enhances microglial phagocytosis to attenuate cerebral ischemia-reperfusion injury through the ChemR23/p38 MAPK pathway.iScience · 2025Article
- Editorial for the Special Issue: Recent Advances in Adipokines-2nd Edition.Biomedicines · 2025Article
- Weight of time: exploring the link between obesity and aging.Aging clinical and experimental research · 2025Review
- Vascular effects of perivascular adipose tissue-derived chemerin in obesity-associated cardiovascular disease.Cardiovascular diabetology · 2025Review
- Structural insights into the distinct ligand recognition and signaling of the chemerin receptors CMKLR1 and GPR1.Protein & cell · 2025Article
- Effect of adipokines on bone marrow mesenchymal stem cell function.World journal of stem cells · 2025Review
44 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Overweight and adiposity are risk factors for several diseases, like type 2 diabetes and cancer. White adipose tissue is a major source for adipokines, comprising a diverse group of proteins exerting various functions. Chemerin is one of these proteins whose systemic levels are increased in obesity. Chemerin is involved in different physiological and pathophysiological processes and it regulates adipogenesis, insulin sensitivity, and immune response, suggesting a vital role in metabolic health. The majority of serum chemerin is biologically inert. Different proteases are involved in the C-terminal processing of chemerin and generate diverse isoforms that vary in their activity. Distribution of chemerin variants was analyzed in adipose tissues and plasma of lean and obese humans and mice. The Tango bioassay, which is suitable to monitor the activation of the beta-arrestin 2 pathway, was used to determine the ex-vivo activation of chemerin receptors by systemic chemerin. Further, the expression of the chemerin receptors was analyzed in adipose tissue, liver, and skeletal muscle. Present investigations assume that increased systemic chemerin in human obesity is not accompanied by higher biologic activity. More research is needed to fully understand the pathways that control chemerin processing and chemerin signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.